Home > Analytics > KILITCH DRUGS (INDIA)

KILITCH DRUGS (INDIA)
Intrinsic Value | Fundamental Analysis

BOM : 524500     NSE : KILITCH    
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Mild Upward
Pledged Shares : None or < 25%
Sep 27,2022
Price(EOD): ₹ 167.05
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 260.60 Cr
Value of ₹ 1 Lac invested in KILITCH DRUGS (INDIA)
on Sep 27,2017 (price: ₹ 61.85)

₹ 1 L

₹ 2.70 L

1W : 1.1% 1M : 3.2% 1Y : -2.2%
COMMUNITY POLL
for KILITCH DRUGS (INDIA)
Please provide your vote to see the results
Industry Peers & Returns1W1M1Y
KILITCH DRUGS (INDIA) 1.1% 3.2% -2.2%
SUN PHARMACEUTICAL INDUSTRIES -0.9% 2% 16.6%
DIVIS LABORATORIES 2.9% 2.5% -29.2%
DR REDDYS LABORATORIES 0.8% -1% -14.9%
CIPLA 3% 7.9% 10.1%
GLAND PHARMA -5% -13.5% -47.2%
PIRAMAL ENTERPRISES -8.3% -55.7% -68%
CADILA HEALTHCARE -1.6% -5.7% -37.2%
TORRENT PHARMACEUTICALS 2.2% -0.9% -2.4%

FUNDAMENTAL ANALYSIS OF KILITCH DRUGS (INDIA)

 
Fundamentals Score
[ Q(TTM): Jun2022, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF KILITCH DRUGS (INDIA)

 
Valuation Score
[As on : Sep 27,2022 ]

Ratio Consolidated
P/E
P/B
P/S
36
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 7.23 Cr
[Latest Qtr - Jun2022 - Consolidated Results ]

1.87
P/B Calculated based on Book Value of Rs 139.09 Cr
[Latest Year - Mar2022 - Consolidated Results ]

2.03
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 128.06 Cr
[Latest Qtr - Jun2022 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 17% undervalued companies ! Discover More →

FAIR VALUE OF KILITCH DRUGS (INDIA)

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
563%
46%
87%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF KILITCH DRUGS (INDIA)



KILITCH DRUGS (INDIA) vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF KILITCH DRUGS (INDIA)

Year Debt/Equity ratio
Standalone Consolidated
2021
2020
2019
Avg_3yrs
0.09
0.08
0.06
0.08
0.12
0.11
0.08
0.1
[Last Annual Data : Mar2021]
Financial Ratios →

PLEDGED PROMOTER SHARES OF KILITCH DRUGS (INDIA)

Pledged Promoter Shares
0 %
As on : Jun2022

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF KILITCH DRUGS (INDIA)

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-8.62%
-32.24%
-19.22%
-24.52%
70.46%
278.74%
108.95%
141.11%
QtrlyTrend
0
Latest Qtr: Jun2022
Quarterly Result Analysis →


KILITCH DRUGS (INDIA) related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about KILITCH DRUGS (INDIA)


Is KILITCH DRUGS (INDIA) good for long term investment?

As on Sep 27,2022, the Fundamentals of KILITCH DRUGS (INDIA) look Poor and hence it may not be good for long term investment ! See Financial Performance of KILITCH DRUGS (INDIA) . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is KILITCH DRUGS (INDIA) UnderValued or OverValued?

As on Sep 27,2022, KILITCH DRUGS (INDIA) is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of KILITCH DRUGS (INDIA) ?

As on Sep 27,2022, the Intrinsic Value of KILITCH DRUGS (INDIA) is Rs. 89.48 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 25.21
Fair Value [Median EV / Sales Model] : Rs. 114.30
Fair Value [Median Price / Sales Model] : Rs. 89.48
Estimated Median Fair Value of KILITCH DRUGS (INDIA) : Rs. 89.48

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is KILITCH DRUGS (INDIA) trading at a Premium or Discount?

As on Sep 27,2022, KILITCH DRUGS (INDIA) is trading at a Premium of 87% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].